---
title: "Soligenix raises at‑market share capacity by $2.956M under sales agreement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287974515.md"
description: "Soligenix has increased the maximum amount of common stock available for sale under its at-market sales agreement by $2,956,000. A prospectus supplement was filed on May 28, 2026, to boost the sales capacity. Previously, approximately $3,445,000 of common stock was sold under the same agreement."
datetime: "2026-05-28T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287974515.md)
  - [en](https://longbridge.com/en/news/287974515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287974515.md)
---

# Soligenix raises at‑market share capacity by $2.956M under sales agreement

**Soligenix increased the maximum amount of common stock available for sale under its at‑market sales agreement by $2,956,000.**

**Key Highlights:**

-   Filed a prospectus supplement on May 28, 2026 to boost the Sales Agreement capacity by $2,956,000.
-   Previously sold approximately $3,445,000 of common stock under the same Sales Agreement.
-   Legal opinion regarding the $2,956,000 of shares is filed as Exhibit 5.1 with the filing.

Original SEC Filing: SOLIGENIX, INC. \[ SNGX \] - 8-K - May. 28, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

- [Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine | SNGX Stock News](https://longbridge.com/en/news/289047958.md)
- [Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives](https://longbridge.com/en/news/284380828.md)
- [UBS Study: Family Offices Increasingly Focus on Diversification and AI](https://longbridge.com/en/news/287892425.md)
- [Apple stock hits record as AI bets grow ahead of WWDC](https://longbridge.com/en/news/287893387.md)
- [Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma | SNGX Stock News](https://longbridge.com/en/news/284374035.md)